A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
R. Hájek*, T. Masszi, M. T. Petrucci, A. Palumbo, L. Rosiñol, A. Nagler, K. L. Yong, A. Oriol, J. Minarik, L. Pour, M. A. Dimopoulos, V. Maisnar, D. Rossi, H. Kasparu, J. Van Droogenbroeck, D. B. Yehuda, I. Hardan, M. Jenner, M. Calbecka, M. DávidJ. De La Rubia, J. Drach, Z. Gasztonyi, S. Górnik, X. Leleu, M. Munder, M. Offidani, N. Zojer, K. Rajangam, Y. L. Chang, J. F. San-Miguel, H. Ludwig
*Corresponding author for this work
Research output: Contribution to journal › Article › peer-review
103Scopus
citations
Fingerprint
Dive into the research topics of 'A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)'. Together they form a unique fingerprint.